Mural Oncology’s (MURA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Mural Oncology (NASDAQ:MURA) in a research report released on Wednesday,Benzinga reports. The brokerage currently has a $18.00 price objective on the stock.

Mural Oncology Stock Performance

Shares of MURA opened at $3.90 on Wednesday. The company has a 50-day simple moving average of $3.86 and a 200-day simple moving average of $3.58. The firm has a market capitalization of $67.19 million, a P/E ratio of -0.43 and a beta of 3.66. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.12.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same period in the previous year, the business earned ($3.57) EPS. As a group, equities analysts forecast that Mural Oncology will post -7.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MURA. Acorn Capital Advisors LLC acquired a new position in Mural Oncology in the fourth quarter worth about $4,141,000. Point72 Asset Management L.P. acquired a new position in Mural Oncology in the third quarter worth about $340,000. Raymond James Financial Inc. acquired a new position in Mural Oncology in the fourth quarter worth about $181,000. Virtu Financial LLC bought a new stake in Mural Oncology during the fourth quarter worth about $129,000. Finally, Renaissance Technologies LLC grew its stake in Mural Oncology by 17.4% during the fourth quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock worth $768,000 after buying an additional 35,403 shares during the last quarter. Institutional investors and hedge funds own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.